3 Pharma Stocks to Dump Before the Damage Is Done
Beware! 3 Biotech Stocks Waving Massive Red Flags Right Now
Are Medical Stocks Lagging Axcella Health (AXLA) This Year?
Why Is Axcella Health (AXLA) Stock Down 24% Today?
Axcella Announces Reverse Stock Split Effective September 19, 2023
Why Is Axcella Health (AXLA) Stock Down 21% Today?
Axcella (AXLA) Up on Patent Grant for Long Covid Fatigue Drug
Why Is Axcella Health (AXLA) Stock Up 280% Today?
Axcella Health stock rockets on long Covid patent win
Axcella Granted Patent for Long COVID Fatigue Treatment
Why Is Axcella Health (AXLA) Stock Up 68% Today?
Axcella Reports Second Quarter Financial Results and Provides Business Update
Axcella Reports First Quarter Financial Results and Provides Business Update
Axcella Reports First Quarter Financial Results and Provides Business Update
Axcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023
Axcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023
Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Why Is Axcella Health (AXLA) Stock Up 35% Today?
Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue
Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue
Axcella Therapeutics to Participate in the SVB Securities' 2023 Global Biopharma Conference
Axcella Therapeutics to Participate in the SVB Securities’ 2023 Global Biopharma Conference
Penny Stocks To Buy Now? 7 To Watch With Big News this Week
4 Penny Stocks To Watch With Big News This Week
Why Is Axcella Health (AXLA) Stock Up 66% Today?
Axcella Announces Regulatory Path to Registration of AXA1125 for Long COVID Fatigue
Axcella Announces Regulatory Path to Registration of AXA1125 for Long COVID Fatigue
How to Find Undervalued Penny Stocks: Quick Guide
Axcella Announces Program Reprioritization and Corporate Restructuring
Axcella Announces Program Reprioritization and Corporate Restructuring
Axcella Health Inc. (AXLA) Loses 47.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Axcella to Present at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
Axcella to Present at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
Axcella Health Inc. (AXLA) Q3 2022 Earnings Call Transcript
Axcella Reports Third Quarter Financial Results and Provides Business Update
Axcella Reports Third Quarter Financial Results and Provides Business Update
Axcella Therapeutics to Report Third Quarter 2022 Financial Results on November 1, 2022
Axcella Therapeutics to Report Third Quarter 2022 Financial Results on November 1, 2022
Axcella Therapeutics to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference
Axcella Therapeutics Announces $34.2 Million Registered Direct Offering of Common Stock Priced At The Market: Appoints Two New Board Members
Axcella Therapeutics Announces $34.2 Million Registered Direct Offering of Common Stock Priced At The Market: Appoints Two New Board Members
Axcella's stock is up 10% after sharing new data for its NASH treatment
Axcella Announces Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis (NASH)
Axcella Announces Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis (NASH)
Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
Axcella Reports Second Quarter Financial Results and Provides Business Update
5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID